Reporting from the Milken Conference: The Promise of Medical Science
An excellent perspective on the Medical Sciences in a panel by leading scientists was presented Monday at the Milken Institute Global Conference, "Shaping the Future" at the Beverly Hilton in Los Angeles May 2-4. Over 3000 people attended the Conference attesting to the market recovery since...
Profit Taking Hits Biotechnology Stocks
Biotechnology Sector Steps Back after Meteoric Rise Since Early March With many life science indices reaching new highs both YTD and in some cases over 10 years traders decided it was time to put away some cash. Don't fret yet as we are still way above March lows and still up over 10% YTD. But...
Health and Biotechnology: A Top Performing Sector YTD Up 13.2%
According to data compiled by the Wall Street Journal on Monday May 2 page R8, the Health and Biotechnology sectors led the market (excluding gold oriented funds) in 2011 up 13.2% YTD and 6.7% in April.In the number two position was small cap growth up 13% and mid cap growth up 10.3%. Two...
Rayno Diagnostics and Tools Market Update: GenProbe (GPRO),Illumina (ILMN),Quidel (QDEL)
Earnings season has begun with good results. Keep in mind the following trends: technology convergence, molecular diagnostics and M&A. The backdrop for the tools market is proposed government cuts in government scientific spending especially NIH. Leerink Swann data from the Dept. of Health...
Rayno Life Science Portfolio Dx and Tools: GenProbe (GPRO) Soars On “For Sale”
Earnings season for diagnostics and tools companies begins today with GenProbe (GPRO $79.39) after the market close. But the stock is up 13% today on a Bloomberg scoop that the Company has hired Morgan Stanley as an investment banker to seek a buyer. The market cap is $3.8B with a 2011...